➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
McKesson
Johnson and Johnson
Baxter

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,000,011

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,000,011 protect, and when does it expire?

Patent 9,000,011 protects GALAFOLD and is included in one NDA.

This patent has thirty-six patent family members in seventeen countries.

Summary for Patent: 9,000,011
Title:Methods for treatment of Fabry disease
Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
Inventor(s): Lockhart; David (Del Mar, CA), Castelli; Jeff (New Hope, PA)
Assignee: Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:13/445,338
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,000,011

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Theraps Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,000,011

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007253900   Start Trial
Canada 2652553   Start Trial
Cyprus 1115180   Start Trial
Cyprus 1117656   Start Trial
Denmark 2533050   Start Trial
Denmark 2787345   Start Trial
European Patent Office 2024745   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Medtronic
Dow
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.